Preferences help
enabled [disable] Abstract
Number of results
2018 | 104 | 245-256
Article title

Impact of biological treatment on intestinal microbiom in children with Crohn’s disease

Title variants
Languages of publication
Crohn’s disease (CD) is a chronic, inflammatory illness of the digestive tract, characterized by alternating periods of remission and recurrence. The pathogenesis of CD is still unclear but probably is a result of a complex interaction between immunological, genetic and microbiological disorders. In recent years, there has been an increasing extent of evidence that gut microbiota plays a very important role in the pathogenesis of CD. Currently, the most effective treatment is biological therapy using anti-TNF monoclonal antibodies. It is interesting whether biological drugs resulting in fast remission, contributes to the normalization of the gut microbiota. Due to the fact that the children’s population is a significant percentage of all patients with CD, it is important to pay close attention to the problem of microbiological disorders in this age group. The aim of this study was to investigate whether there are quantitative changes of chosen bacteria species and fungi of the genus Candida in children with Crohn's disease relative to healthy children and assesment of quantitative changes in patients after biological treatment. In the group of children with Crohn’s disease, the numbers in Candida were significantly higher (9.74×1017 CFU/g) than in the control group (9.35×1010 CFU/g, p = 0.011). Biological therapy led to a significant reduction in the amount Candida (5.91×1011) and was comparable with the number in the control group. In the case of bacteria, we observed an increase in S. marcescens (3,4×108) in the patients group compared to the controls (1,85×108) and an increase in L. fermentum (2,34×1010) in relation to healthy children (3,31×108, p = 0,048) Biological treatment had an impact on the decrease in L. fermentum (4,76×109, p = 0.05).
Physical description
  • Faculty of Biotechnology and Horticulture, University of Agriculture in Cracow, Al. 29 Listopada 54, 31-425, Cracow, Poland
  • Department of Molecular Medical Microbiology, Chair of Microbiology, Faculty of Medicine, Jagiellonian University, Medical College, Cracow, Poland
  • Department of Pediatrics, Gastroenterology and Nutrition, Jagiellonian University, Medical College, Cracow, Poland
  • Department of Pediatrics, Gastroenterology and Nutrition, Jagiellonian University, Medical College, Cracow, Poland
  • Department of Molecular Medical Microbiology, Chair of Microbiology, Faculty of Medicine, Jagiellonian University, Medical College, Cracow, Poland
  • Department of Molecular Medical Microbiology, Chair of Microbiology, Faculty of Medicine, Jagiellonian University, Medical College, Cracow, Poland
  • [1] B.A. Hendrickson, R. Gokhale, J.H. Cho.: Clinical aspects and Pathophysiology of Inflammatory Bowel Disease. Clin Microbiol. Rev 2002 Jan15(1): 79-94.
  • [2] C. Fiocchi. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998 Jul: 115(1): 182-205
  • [3] B. Khor, A Gardet., R.J. Xavier. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-17
  • [4] K. Fyderek, M. Strus, K. Kowalska-Duplaga, T. Gosiewski, A. Wędrychowicz, U. Jedynak-Wąsowicz, M. Sładek, S. Pieczarkowski, P. Adamski, P. Kochan, P.B. Heczko: Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J Gastroenterol. (2009); 15, 5287-5294
  • [5] D.N. Frank, A.L.St. Amand, R.A Feldman, E.C. Boedeker, N. Harpaz, N.R. Pace: Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory disease. Proc Natl Acad Sci USA. 2007 Aug 21; 104(34): 13780–13785.
  • [6] I.Ignyś, P. Piątkowska, D. Roszak: Enteric microflora and inflammatory bowel disease development in children; Journal Medical Science, 2007: 76, 1, 59-64
  • [7] M. Jeyanathan, O. Boutros-Tadros, J. Radhi, M. Semret, A. Bitton, M.A. Behr: Visualization of Mycobacterium avium in Crohn’s tissue by oil-immersion microscopy Microbes Infect. 2007, 9(14-15): 1567-73
  • [8] Franczuk., E.K. Jagusztyn-Krynicka 2012: Role of microbiota in Crohn’s disease induction in the light of studies of Human Microbiome Project Post. Mikrobiol. 51,4, 257-264
  • [9] E. Krzesiek: Postępy w leczeniu nieswoistych zapaleń jelit, Nowa Pediatria 3/2002, s. 179-184
  • [10] J.S. Hyams, G.D. Ferry, F.S. Mandel, J.D. Gryboski, P.M. Kibort, B.S. Kirschner, A.M. Griffiths, A.J Katz, R.J. Grand, J.T Boyle: Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991 May; 12(4): 439-47.
  • [11] A.M. Thomas, Eliane C. Jesus,A. Lopes, S. Aguiar, Jr., M. D. Begnami, R.M. Rocha, P.A. Carpinetti, A. A. Camargo, C. Hoffmann, H. C. Freitas, Is. T. Silva, D. N. Nunes, J. C. Setubal, E. Dias-Neto: Tissue-Associated Bacterial Alterations in Rectal Carcinoma Patients Revealed by 16S rRNA Community Profiling Front Cell Infect Microbiol. 2016; 6: 179.
  • [12] M. Haarman, J. Knol:. Quantitative real-time PCR analysis of fecal Lactobacillus species in infants receiving a prebiotic infant formula. Appl Environ Microbiol (2006) Apr; 72(4): 2359-65.
  • [13] J. Joyner, D. Wanless, C.D. Sinigalliano, E.K. Lipp : Use of Quantitative Real-Time PCR for Direct Detection of Serratia marcescens in Marine and Other Aquatic Environments, Appl Environ Microbiol. 2014 Mar; 80(5): 1679-83
  • [14] J. Shchepetowa E. Sepp, H. Kolk, K. Loivukene: Diversity and metabolic impact of intestinal Lactobacillus species in healthy adults and the elderly, British Journal of Nutrition (2011): 105, 1235–1244
  • [15] T. Gosiewski, D. Salamon, M. Szopa, A.Sroka, M.T. Malecki, M. Bulanda: Quantitative evaluation of fungi of the genus Candida in the feces of adult patients with type 1 and 2 diabetes - a pilot study. Gut Pathog. 2014; 6: 43.
  • [16] R.B. Sartor: Microbial influences in Inflammatory Bowel Disease; Gastroenterology 2008, 134(2): 577-94
  • [17] Swidsinski, J. Weber, V. Loening-Baucke, L. P. Hale, H.Lochs : Spatial Organization and Composition of the Mucosal Flora in Patients with Inflammatory Bowel Disease, J Clin Microbiol. 2005 Jul; 43(7): 3380–3389.
  • [18] Y. Zhou, H. Chen, H. He, Y. Du, J.Hu, Y. Li, Y. Li, Y. Zhou, H. Wang, Y. Chen, Y. Nie: Increased Enterococcus faecalis infection is associated with clinically active Crohn disease. Medicine (Baltimore). 2016 Sep; 95(39): e5019.
  • [19] I. Ignyś. P. Piątkowska. D. Roszak. Enteric microflora and inflammatory bowel disease development in children, Journal of Medical Science 2007, (76, 1): 59-64
  • [20] G. Hoarau., K. Mukherjee., C. Gower-Rousseau., C. Hager., J. Chandra, M.A. Retuerto, C. Neut, S. Vermeire, J. Clemente, J.F. Colombel, H. Fujioka, D. Poulain, B. Sendid, M.A. Ghannoum: Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohn’s Disease. Mbio 2016 7(5). e01250-16
  • [21] I.D. Iliev, V.A. Funari , K.D. Taylor, Q. Nguyen, C.N. Reyes, S.P. Strom, J. Brown, C.A. Becker, P.R. Fleshner, M. Dubinsky, J.I. Rotter, H.L. Wang, D.P. McGovern, G.D. Brown, D.M. Underhill: Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis; Science. 2012, 336(6086): 1314–1317
  • [22] W. Wang, L. Chen, R. Zhou, X. Wang, L. Song, S. Huang, G. Wang, B. Xia: Increased Proportions of Bifidobacterium and the Lactobacillus Group and Loss of Butyrate-Producing Bacteria in Inflammatory Bowel Disease, J Clin Microbiol. 2014 Feb; 52(2): 398–406
  • [23] M.H. Giaffer, C.D. Holdsworth, B.I. Duerden: The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. Journal of Medical Microbiology 35: 238-243, 1991
  • [24] K. Borycka-Kiciak., M. Strus, P. Pietrzak, A. Kiciak, K. Wawiernia, D. Mikołajczyk, M. Gałęcka, P. Heczko, W. Tarnowski: Clinical and microbiological aspects of use of Lactobacillus rhamnosus PL1 strains in proctologic patients with symptoms of chronic proctitis. Pol Przegl Chir. 2017 Jun 30;89(3):16-22.
  • [25] M. Kotowska, P. Albrecht, Review of clinical trials on Lactobacillus rhamnosus GG Forum Zakażeń 5(2), 2014, 111−119.
  • [26] M. Schultz, A. Timmer, H.H. Herfarth, R.B. Sartor, J.A. Vanderhoof, H.C. Rath: Lactobacillus GG in inducing and maintaining remission of Crohn's disease, BMC Gastroenterol. 2004; 4: 5.
  • [27] C. Prantera, M.L. Scribano, G. Falasco, A. Andreoli, C. Luzi: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51:405–409
  • [28] P Patlevic, J Vaskova, P Svorc Jr, L Vasko, P Svorc: Reactive oxygen species and antioxidant defense in human gastrointestinal disease Integr Med Res 2016 250-258
  • [29] Y.L. Song, N. Kato, N. Matsumiya, CX. Liu, H. Kato, K. Watanabe: Identification of and Hydrogen Peroxide Production by Fecal and Vaginal Lactobacilli Isolated from Japanese Women and Newborn Infants, Journal of Clinical Microbiology, 1999, 3062-3064
  • [30] R.C. Anderson, W. Young, S. Clerens, A.L. Cookson, M.J. McCann, K.M. Armstrong, N.C. Roy: Human Oral Isolate of Lactobacillus fermentum AGR1487 Reduces Intestinal Barrier Integrity by Increasing the Turnover of Microtubules in Caco2-Cells, PLOS one (2013), vol. 8, issue 11, e78774
  • [31] R.C. Anderson, D. Ulluwishewa W. Young, L.J. Ryan, G. Henderson, M. Meijerink, E. Maier, J.M. Wells, N.C. Roy: Human oral isolate Lactobacillus fermentum AGR1487 induces a proinflammatory response in germfree rat colons, Nature, Scientific Reports (2015) | 6:20318 | DOI: 10.1038/srep20318
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.